Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Untch

Showing results (311-320 of 377) with videos related to

Pageof 38
Sort By:
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast CancerDiana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 1 - Early Stage Breast CancerAndreas D Hartkopf, Tanja N Fehm, Manfred Welslau, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast CancerMichael P Lux, Andreas D Hartkopf, Tanja N Fehm, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast CancerWolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
Pageof 38

Showing results (311-320 of 377) with videos related to

Sort By:
Pageof 38
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 3 - Patients with Advanced Stage Breast CancerDiana Lüftner, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 1 - Early Stage Breast CancerAndreas D Hartkopf, Tanja N Fehm, Manfred Welslau, et al.
Geburtshilfe Und Frauenheilkunde|November 2, 2023
Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast CancerMichael P Lux, Andreas D Hartkopf, Tanja N Fehm, et al.
Geburtshilfe Und Frauenheilkunde|May 19, 2025
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast CancerWolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, et al.
The New England Journal of Medicine|March 20, 2024
Ribociclib plus Endocrine Therapy in Early Breast CancerDennis Slamon, Oleg Lipatov, Zbigniew Nowecki, et al.
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
The Lancet. Oncology|July 12, 2021
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trialsCarsten Denkert, Fenja Seither, Andreas Schneeweiss, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
The New England Journal of Medicine|December 10, 2025
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast CancerSibylle Loibl, Yeon Hee Park, Zhiming Shao, et al.
Pageof 38